Hang Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hang Xue has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Guohui Liu
Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 shared publications - Yuan Xiong
Department of Orthopaedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 shared publications Chenchen Yan
Department of Orthopedics Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China hust.edu.cn
7 shared publicationsYiqiang Hu
Department of Orthopedics Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan People's Republic of China
6 shared publications- Adriana C. Panayi
Department of Oral and Maxillofacial Surgery, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
5 shared publications - Bobin Mi
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
5 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Wiley in Advanced Science
CaSiO 3 ‐Engineered Extracellular Vesicles Promote Diabetic Fracture Healing in Mice via the PGC‐1α–miR‐363‐3p–DKK3–β‐Catenin Axis
Diabetes impairs fracture healing. In diabetic mice, we found that PGC‐1α expression is downregulated in bone marrow mesenchymal stem cell (BMSC). PGC‐1α levels positively correlate with osteogenic capacity. Physiologically, reduced PGC‐1α suppresses miR‐363‐3p expression; mechanistically, this further inhibits DKK3, thereby promoting β‐catenin phosphorylation and degradation, which in turn inhibits osteogenesis in BMSCs. To target this pathway, we treated BMSC with calcium silicate (CaSiO 3 ). CaSiO 3 inhibited the ubiquitination‐mediated degradation of PGC‐1α, restoring miR‐363‐3p expression. It also upregulated AGO2, which facilitated the assembly of miR‐363‐3p into mi‐RISC complexes and their loading into extracellular vesicles. We then engineered a ROS‐responsive hydrogel (Gel ROS ) to deliver these CaSiO 3 ‐engineered extracellular vesicles (EVs). In diabetic mice with femoral fractures, the hydrogel enabled sustained, on‐demand release of EVs specifically at sites with high ROS levels. The released EVs, enriched with miRISC complexes, suppressed the DKK3‐β‐catenin axis in recipient BMSC, enhanced osteogenesis, and accelerated fracture healing. This study identifies the PGC‐1α–miR‐363‐3p–DKK3‐β–catenin axis as a key pathway in diabetic fracture healing. It also presents a novel EVs‐based strategy that avoids direct CaSiO 3 toxicity, offering a new translational approach for treating diabetic bone defects.
- 18 November 2026
- Published by Wiley in Advanced Science
Open AccessCaSiO 3 ‐Engineered Extracellular Vesicles Promote Diabetic Fracture Healing in Mice via the PGC‐1α–miR‐363‐3p–DKK3–β‐Catenin Axis
Diabetes impairs fracture healing. In diabetic mice, we found that PGC‐1α expression is downregulated in bone marrow mesenchymal stem cell (BMSC). PGC‐1α levels positively correlate with osteogenic capacity. Physiologically, reduced PGC‐1α suppresses miR‐363‐3p expression; mechanistically, this further inhibits DKK3, thereby promoting β‐catenin phosphorylation and degradation, which in turn inhibits osteogenesis in BMSCs. To target this pathway, we treated BMSC with calcium silicate (CaSiO 3 ). CaSiO 3 inhibited the ubiquitination‐mediated degradation of PGC‐1α, restoring miR‐363‐3p expression. It also upregulated AGO2, which facilitated the assembly of miR‐363‐3p into mi‐RISC complexes and their loading into extracellular vesicles. We then engineered a ROS‐responsive hydrogel (Gel ROS ) to deliver these CaSiO 3 ‐engineered extracellular vesicles (EVs). In diabetic mice with femoral fractures, the hydrogel enabled sustained, on‐demand release of EVs specifically at sites with high ROS levels. The released EVs, enriched with miRISC complexes, suppressed the DKK3‐β‐catenin axis in recipient BMSC, enhanced osteogenesis, and accelerated fracture healing. This study identifies the PGC‐1α–miR‐363‐3p–DKK3‐β–catenin axis as a key pathway in diabetic fracture healing. It also presents a novel EVs‐based strategy that avoids direct CaSiO 3 toxicity, offering a new translational approach for treating diabetic bone defects.
- Open Access
- 1 September 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 63, 484-505
Polysaccharide-engineered mitochondria reprogram macrophages to resolve diabetic wound inflammation and promote repair
Chronic diabetic wounds are characterized by persistent inflammation, defective resolution and impaired tissue regeneration, in which macrophage dysfunction and mitochondrial damage play central roles. Here, we developed a macrophage-targeted engineered mitochondrial transplantation system by coating adipose-derived stem cell (ADSC) mitochondria with triphenylphosphonium-modified konjac glucomannan (Mito-TPP-KGM). This design preserves mitochondrial membrane potential and ATP production while reducing ROS generation, and provides a mannose-rich corona for lectin receptor-related uptake. In RAW264.7 macrophages exposed to high glucose plus H2O2 or LPS, Mito-TPP-KGM is efficiently internalized, restores mitochondrial homeostasis, rebalances glycolysis and oxidative phosphorylation, and shifts inflammatory profiles toward a less inflammatory and more reparative phenotype. Engineered mitochondria also restore efferocytosis of apoptotic neutrophil-like cells and enhance the pro-angiogenic capacity of macrophage-conditioned media, thereby improving endothelial tube formation, migration and proliferation. Blocking experiments with mannan and anti-CD206/anti-DC-SIGN antibodies, together with species-specific mtDNA quantification, indicate that mannose-type lectin receptors contribute to the uptake and immunomodulatory effects of Mito-TPP-KGM. In a db/db mouse full-thickness wound model, local delivery of Mito-TPP-KGM promotes wound repair, improves histological healing, reduces oxidative damage, enhances angiogenesis, and modulates wound macrophage phenotype, leading to accelerated wound closure; these therapeutic benefits are partially attenuated by local CD206 blockade. Collectively, these findings demonstrate that polysaccharide-engineered mitochondria can reprogram diabetic wound macrophages via targeted mitochondrial transplantation, offering a promising immunometabolic strategy for chronic wound therapy.
- 1 September 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 63, 484-505
Open AccessPolysaccharide-engineered mitochondria reprogram macrophages to resolve diabetic wound inflammation and promote repair
Chronic diabetic wounds are characterized by persistent inflammation, defective resolution and impaired tissue regeneration, in which macrophage dysfunction and mitochondrial damage play central roles. Here, we developed a macrophage-targeted engineered mitochondrial transplantation system by coating adipose-derived stem cell (ADSC) mitochondria with triphenylphosphonium-modified konjac glucomannan (Mito-TPP-KGM). This design preserves mitochondrial membrane potential and ATP production while reducing ROS generation, and provides a mannose-rich corona for lectin receptor-related uptake. In RAW264.7 macrophages exposed to high glucose plus H2O2 or LPS, Mito-TPP-KGM is efficiently internalized, restores mitochondrial homeostasis, rebalances glycolysis and oxidative phosphorylation, and shifts inflammatory profiles toward a less inflammatory and more reparative phenotype. Engineered mitochondria also restore efferocytosis of apoptotic neutrophil-like cells and enhance the pro-angiogenic capacity of macrophage-conditioned media, thereby improving endothelial tube formation, migration and proliferation. Blocking experiments with mannan and anti-CD206/anti-DC-SIGN antibodies, together with species-specific mtDNA quantification, indicate that mannose-type lectin receptors contribute to the uptake and immunomodulatory effects of Mito-TPP-KGM. In a db/db mouse full-thickness wound model, local delivery of Mito-TPP-KGM promotes wound repair, improves histological healing, reduces oxidative damage, enhances angiogenesis, and modulates wound macrophage phenotype, leading to accelerated wound closure; these therapeutic benefits are partially attenuated by local CD206 blockade. Collectively, these findings demonstrate that polysaccharide-engineered mitochondria can reprogram diabetic wound macrophages via targeted mitochondrial transplantation, offering a promising immunometabolic strategy for chronic wound therapy.
- 22 March 2024
- Published by Springer Nature in Multimedia Systems
- Vol. 30 (2) , 1-12
SMA-GCN: a fall detection method based on spatio-temporal relationship
- 22 March 2024
- Published by Springer Nature in Multimedia Systems
- Vol. 30 (2) , 1-12
SMA-GCN: a fall detection method based on spatio-temporal relationship
- Open Access
- 24 May 2023
- Published by Wiley in Stem Cells International
- Vol. 2023, 1-10
Melatonin Promotes BMSCs Osteoblastic Differentiation and Relieves Inflammation by Suppressing the NF-κB Pathways
Bone mesenchymal stem cells (BMSCs) play an important role in maintaining the dynamic balance of bone metabolism. Recent studies have reported that a decrease in the osteogenic function of MSCs is strongly associated with osteoporosis. Melatonin is a neuroendocrine hormone produced in the pineal gland and is essential in the physiological regulation. This study is aimed at exploring the effect of melatonin on MSCs osteoblastic differentiation and elucidate the underlying mechanisms. We isolated BMSCs from rat bone marrow and demonstrated that melatonin improved osteogenic differentiation of BMSCs by the alizarin red staining and ALP staining. We then showed that melatonin enhanced osteogenic gene expression in BMSCs, including ALP, Col 1, OCN, OPN, and RUNX2. We further revealed that melatonin inhibited the inflammatory response of BMSCs by suppressing the NF-κB signaling pathways. In light of this, we found that the NF-κB pathway-specific activator TNF-α activated the NF-κB pathway, inhibited osteogenic differentiation, and induced inflammatory response in BMSCs. Melatonin was found to reverse the inhibitory effect of TNF-α on osteogenic differentiation and inflammation in BMSCs. Taken together, these findings indicated that melatonin may have therapeutic potential to be used for the treatment of osteoporosis.
- 24 May 2023
- Published by Wiley in Stem Cells International
- Vol. 2023, 1-10
Open AccessMelatonin Promotes BMSCs Osteoblastic Differentiation and Relieves Inflammation by Suppressing the NF-κB Pathways
Bone mesenchymal stem cells (BMSCs) play an important role in maintaining the dynamic balance of bone metabolism. Recent studies have reported that a decrease in the osteogenic function of MSCs is strongly associated with osteoporosis. Melatonin is a neuroendocrine hormone produced in the pineal gland and is essential in the physiological regulation. This study is aimed at exploring the effect of melatonin on MSCs osteoblastic differentiation and elucidate the underlying mechanisms. We isolated BMSCs from rat bone marrow and demonstrated that melatonin improved osteogenic differentiation of BMSCs by the alizarin red staining and ALP staining. We then showed that melatonin enhanced osteogenic gene expression in BMSCs, including ALP, Col 1, OCN, OPN, and RUNX2. We further revealed that melatonin inhibited the inflammatory response of BMSCs by suppressing the NF-κB signaling pathways. In light of this, we found that the NF-κB pathway-specific activator TNF-α activated the NF-κB pathway, inhibited osteogenic differentiation, and induced inflammatory response in BMSCs. Melatonin was found to reverse the inhibitory effect of TNF-α on osteogenic differentiation and inflammation in BMSCs. Taken together, these findings indicated that melatonin may have therapeutic potential to be used for the treatment of osteoporosis.
- Open Access
- 27 October 2022
- Published by MDPI AG in Biosensors
- Vol. 12 (11) , 930
One-Pot Preparation of Imidazole-Ring-Modified Graphitic Carbon Nitride Nanozymes for Colorimetric Glucose Detection
Nanozymes are highly desired to overcome the shortcomings of natural enzymes, such as low stability, high cost and difficult storage during biosensing applications. Herein, by imitating the structure of natural enzymes, we propose a one-pot annealing process to synthesis imidazole-ring-modified graphitic carbon nitride (g-C3N4-Im) with enhanced peroxidase-like activity. g-C3N4-Im shows enhanced peroxidase-like activity by 46.5 times compared to unmodified g-C3N4. Furthermore, imidazole rings of g-C3N4-Im make it possible to anchor Cu(II) active sites on it to produce g-C3N4-Im-Cu, which shows a further increase in peroxidase-like activity by three times. It should be noted that the as-prepared g-C3N4-Im-Cu could show obvious peroxidase-like activity over a broad range of pH values and at a low temperature (5 °C). The ultrahigh peroxidase-like activity is attributed to the electronic effect of imidazole rings and the active sites of Cu(II) for ·OH production. Based on the enhanced peroxidase-like activity, a H2O2 and glucose biosensor was developed with a high sensitivity (limit of detection, 10 nM) and selectivity. Therefore, the biosensor shows potential for applications in diabetic diagnoses in clinical practice.
- 27 October 2022
- Published by MDPI AG in Biosensors
- Vol. 12 (11) , 930
Open AccessOne-Pot Preparation of Imidazole-Ring-Modified Graphitic Carbon Nitride Nanozymes for Colorimetric Glucose Detection
Nanozymes are highly desired to overcome the shortcomings of natural enzymes, such as low stability, high cost and difficult storage during biosensing applications. Herein, by imitating the structure of natural enzymes, we propose a one-pot annealing process to synthesis imidazole-ring-modified graphitic carbon nitride (g-C3N4-Im) with enhanced peroxidase-like activity. g-C3N4-Im shows enhanced peroxidase-like activity by 46.5 times compared to unmodified g-C3N4. Furthermore, imidazole rings of g-C3N4-Im make it possible to anchor Cu(II) active sites on it to produce g-C3N4-Im-Cu, which shows a further increase in peroxidase-like activity by three times. It should be noted that the as-prepared g-C3N4-Im-Cu could show obvious peroxidase-like activity over a broad range of pH values and at a low temperature (5 °C). The ultrahigh peroxidase-like activity is attributed to the electronic effect of imidazole rings and the active sites of Cu(II) for ·OH production. Based on the enhanced peroxidase-like activity, a H2O2 and glucose biosensor was developed with a high sensitivity (limit of detection, 10 nM) and selectivity. Therefore, the biosensor shows potential for applications in diabetic diagnoses in clinical practice.
- Open Access
- 22 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5564604
Clinical Application Study of Minimally Invasive Double‐Reverse Traction in Complex Tibial Plateau Fractures
The aim of this study was to evaluate the clinical application of double-reverse traction for minimally invasive reduction of complex tibial plateau fractures. A retrospective analysis was performed to identify all patients admitted to the Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, from March 2017 to December 2019 with Schatzker type VI tibial plateau fractures. 12 patients were identified (7 men and 5 women) with an average age of (39-58) years old. All patients were treated with double-reverse traction and closed reduction. After the fracture was reduced, the bone plate was fixed by percutaneous minimally invasive implantation. Outcomes assessed in this study include operation time and intraoperative blood loss. Imaging was performed during the postoperative follow-up, and functional recovery was evaluated at the final follow-up according to the Hospital for Special Surgery (HSS) score and the International Knee Joint Literature Committee (IKDC) functional score. Patients were followed up for (8-15) months. The average operation time was (35-120) minutes, and the average intraoperative blood loss was (60-200) mL. The Rasmussen imaging score was either excellent or good in all cases. The knee joint HSS score was (79-90) points, and the IKDC score was (75-90) points. No complications, such as wound infection, incision disunion, loosening of internal fixation, and internal fixation failure, occurred. In the treatment of Schatzker VI type complex tibial plateau fracture, the dual-reverse traction minimally invasive technique has the advantages of safety and effectiveness, less soft tissue injury, and allowing early joint movement, which is worthy of clinical promotion.
- 22 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5564604
Open AccessClinical Application Study of Minimally Invasive Double‐Reverse Traction in Complex Tibial Plateau Fractures
The aim of this study was to evaluate the clinical application of double-reverse traction for minimally invasive reduction of complex tibial plateau fractures. A retrospective analysis was performed to identify all patients admitted to the Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, from March 2017 to December 2019 with Schatzker type VI tibial plateau fractures. 12 patients were identified (7 men and 5 women) with an average age of (39-58) years old. All patients were treated with double-reverse traction and closed reduction. After the fracture was reduced, the bone plate was fixed by percutaneous minimally invasive implantation. Outcomes assessed in this study include operation time and intraoperative blood loss. Imaging was performed during the postoperative follow-up, and functional recovery was evaluated at the final follow-up according to the Hospital for Special Surgery (HSS) score and the International Knee Joint Literature Committee (IKDC) functional score. Patients were followed up for (8-15) months. The average operation time was (35-120) minutes, and the average intraoperative blood loss was (60-200) mL. The Rasmussen imaging score was either excellent or good in all cases. The knee joint HSS score was (79-90) points, and the IKDC score was (75-90) points. No complications, such as wound infection, incision disunion, loosening of internal fixation, and internal fixation failure, occurred. In the treatment of Schatzker VI type complex tibial plateau fracture, the dual-reverse traction minimally invasive technique has the advantages of safety and effectiveness, less soft tissue injury, and allowing early joint movement, which is worthy of clinical promotion.
- RetractedOpen Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1) , 9930524
[Retracted] Nomogram for Predicting Deep Venous Thrombosis in Lower Extremity Fractures
Deep venous thrombosis (DVT) is a common complication in patients with lower extremity fractures, causing delays in recovery short‐term and possible impacts on quality of life long‐term. Early prediction and prevention of thrombosis can effectively reduce patient pain while improving outcomes. Although research on the risk factors for thrombosis is prevalent, there is a stark lack of clinical predictive models for DVT occurrence specifically in patients with lower limb fractures. In this study, we aim to propose a new thrombus prediction model for lower extremity fracture patients. Data from 3300 patients with lower limb fractures were collected from Wuhan Union Hospital and Hebei Third Hospital, China. Patients who met our inclusion criteria were divided into a thrombosis and a nonthrombosis group. A multivariate logistic regression analysis was carried out to identify predictors with obvious effects, and the corresponding formulas were used to establish the model. Model performance was evaluated using a discrimination and correction curve. 2662 patients were included in the regression analysis, with 1666 in the thrombosis group and 996 in the nonthrombosis group. Predictive factors included age, Body Mass Index (BMI), fracture‐fixation types, energy of impact at the time of injury, blood transfusion during hospitalization, and use of anticoagulant drugs. The discriminative ability of the model was verified using the C‐statistic (0.676). For the convenience of clinical use, a score table and nomogram were compiled. Data from two centers were used to establish a novel thrombus prediction model specific for patients with lower limb fractures, with verified predictive ability.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1) , 9930524
RetractedOpen Access[Retracted] Nomogram for Predicting Deep Venous Thrombosis in Lower Extremity Fractures
Deep venous thrombosis (DVT) is a common complication in patients with lower extremity fractures, causing delays in recovery short‐term and possible impacts on quality of life long‐term. Early prediction and prevention of thrombosis can effectively reduce patient pain while improving outcomes. Although research on the risk factors for thrombosis is prevalent, there is a stark lack of clinical predictive models for DVT occurrence specifically in patients with lower limb fractures. In this study, we aim to propose a new thrombus prediction model for lower extremity fracture patients. Data from 3300 patients with lower limb fractures were collected from Wuhan Union Hospital and Hebei Third Hospital, China. Patients who met our inclusion criteria were divided into a thrombosis and a nonthrombosis group. A multivariate logistic regression analysis was carried out to identify predictors with obvious effects, and the corresponding formulas were used to establish the model. Model performance was evaluated using a discrimination and correction curve. 2662 patients were included in the regression analysis, with 1666 in the thrombosis group and 996 in the nonthrombosis group. Predictive factors included age, Body Mass Index (BMI), fracture‐fixation types, energy of impact at the time of injury, blood transfusion during hospitalization, and use of anticoagulant drugs. The discriminative ability of the model was verified using the C‐statistic (0.676). For the convenience of clinical use, a score table and nomogram were compiled. Data from two centers were used to establish a novel thrombus prediction model specific for patients with lower limb fractures, with verified predictive ability.
- Open Access
- 16 April 2020
- Published by Springer Nature in Research Square
M2 Macrophagy-derived Exosomal MiRNA-5106 Induces Bone Mesenchymal Stem Cells towards Osteoblastic Fate by Targeting Salt-inducible Kinase 2 and 3
Background Osteoblast differentiation is a vital process for fracture healing, and exosomes are nanosized membrane vesicles that can deliver therapeutic drugs easily and safely. Macrophages participate in the regulation of various biological processes in vivo , and macrophage-derived exosomes (MD-Exos) have recently been a topic of increasing research interest. However, few study has explored the link between MD-Exos and osteoblast differentiation. Herein, we sought to identify miRNAs differentially expressed between M1 and M2 macrophage-derived exosomes, and to evaluate their roles in the context of osteoblast differentiation. Results We found that microRNA-5106 (miR-5106) was significantly overexpressed in M2 macrophage-derived exosomes (M2D-Exos), while its expression was decreased in M1 macrophage-derived exosomes (M1D-Exos), and we found that this exosomal miRNA can induce bone mesenchymal stem cell (BMSC) osteogenic differentiation via directly targeting the Salt-inducible kinase 2 and 3 ( SIK2 and SIK3 ) genes. In addition, the local injection of both a miR-5106 agonist or M2D-Exos to fracture sites was sufficient to accelerate healing in vivo . Conclusions Our study demonstrates that miR-5106 is highly enriched in M2D-Exos, and that it can be transferred to BMSCs wherein it targets SIK2 and SIK3 genes to promote osteoblast differentiation.
- 16 April 2020
- Published by Springer Nature in Research Square
Open AccessM2 Macrophagy-derived Exosomal MiRNA-5106 Induces Bone Mesenchymal Stem Cells towards Osteoblastic Fate by Targeting Salt-inducible Kinase 2 and 3
Background Osteoblast differentiation is a vital process for fracture healing, and exosomes are nanosized membrane vesicles that can deliver therapeutic drugs easily and safely. Macrophages participate in the regulation of various biological processes in vivo , and macrophage-derived exosomes (MD-Exos) have recently been a topic of increasing research interest. However, few study has explored the link between MD-Exos and osteoblast differentiation. Herein, we sought to identify miRNAs differentially expressed between M1 and M2 macrophage-derived exosomes, and to evaluate their roles in the context of osteoblast differentiation. Results We found that microRNA-5106 (miR-5106) was significantly overexpressed in M2 macrophage-derived exosomes (M2D-Exos), while its expression was decreased in M1 macrophage-derived exosomes (M1D-Exos), and we found that this exosomal miRNA can induce bone mesenchymal stem cell (BMSC) osteogenic differentiation via directly targeting the Salt-inducible kinase 2 and 3 ( SIK2 and SIK3 ) genes. In addition, the local injection of both a miR-5106 agonist or M2D-Exos to fracture sites was sufficient to accelerate healing in vivo . Conclusions Our study demonstrates that miR-5106 is highly enriched in M2D-Exos, and that it can be transferred to BMSCs wherein it targets SIK2 and SIK3 genes to promote osteoblast differentiation.
- Top Cited Papers
- 1 April 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (9) , 750-758
Characteristics and Early Prognosis of COVID-19 Infection in Fracture Patients
Background: Studies of the novel coronavirus-induced disease COVID-19 in Wuhan, China, have elucidated the epidemiological and clinical characteristics of this disease in the general population. The present investigation summarizes the clinical characteristics and early prognosis of COVID-19 infection in a cohort of patients with fractures. Methods: Data on 10 patients with a fracture and COVID-19 were collected from 8 different hospitals located in the Hubei province from January 1, 2020, to February 27, 2020. Analyses of early prognosis were based on clinical outcomes and trends in laboratory results during treatment. Results: All 10 patients presented with limited activity related to the fracture. The most common signs were fever, cough, and fatigue at the time of presentation (7 patients each). Other, less common signs included sore throat (4 patients), dyspnea (5 patients), chest pain (1 patient), nasal congestion (1 patient), headache (1 patient), dizziness (3 patients), abdominal pain (1 patient), and vomiting (1 patient). Lymphopenia (9 cells/L) was identified in 6 of 10 patients, 9 of 9 patients had a high serum level of D-dimer, and 9 of 9 patients had a high level of C-reactive protein. Three patients underwent surgery, whereas the others were managed nonoperatively because of their compromised status. Four patients died on day 8 (3 patients) or day 14 (1 patient) after admission. The clinical outcomes for the surviving patients are not yet determined. Conclusions: The clinical characteristics and early prognosis of COVID-19 in patients with fracture tended to be more severe than those reported for adult patients with COVID-19 without fracture. This finding may be related to the duration between the development of symptoms and presentation. Surgical treatment should be carried out cautiously or nonoperative care should be chosen for patients with fracture in COVID-19-affected areas, especially older individuals with intertrochanteric fractures. Level of Evidence: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
- 1 April 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (9) , 750-758
Top Cited PapersCharacteristics and Early Prognosis of COVID-19 Infection in Fracture Patients
Background: Studies of the novel coronavirus-induced disease COVID-19 in Wuhan, China, have elucidated the epidemiological and clinical characteristics of this disease in the general population. The present investigation summarizes the clinical characteristics and early prognosis of COVID-19 infection in a cohort of patients with fractures. Methods: Data on 10 patients with a fracture and COVID-19 were collected from 8 different hospitals located in the Hubei province from January 1, 2020, to February 27, 2020. Analyses of early prognosis were based on clinical outcomes and trends in laboratory results during treatment. Results: All 10 patients presented with limited activity related to the fracture. The most common signs were fever, cough, and fatigue at the time of presentation (7 patients each). Other, less common signs included sore throat (4 patients), dyspnea (5 patients), chest pain (1 patient), nasal congestion (1 patient), headache (1 patient), dizziness (3 patients), abdominal pain (1 patient), and vomiting (1 patient). Lymphopenia (9 cells/L) was identified in 6 of 10 patients, 9 of 9 patients had a high serum level of D-dimer, and 9 of 9 patients had a high level of C-reactive protein. Three patients underwent surgery, whereas the others were managed nonoperatively because of their compromised status. Four patients died on day 8 (3 patients) or day 14 (1 patient) after admission. The clinical outcomes for the surviving patients are not yet determined. Conclusions: The clinical characteristics and early prognosis of COVID-19 in patients with fracture tended to be more severe than those reported for adult patients with COVID-19 without fracture. This finding may be related to the duration between the development of symptoms and presentation. Surgical treatment should be carried out cautiously or nonoperative care should be chosen for patients with fracture in COVID-19-affected areas, especially older individuals with intertrochanteric fractures. Level of Evidence: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
- Open Access
- 29 January 2020
- Published by Springer Nature in Research Square
Saliva Exosomes-Derived UBE2O Promotes Angiogenesis in Cutaneous Wounds by Targeting SMAD6
Background Enhancing angiogenesis is critical for accelerating wound healing. Application of different types of exosomes (Exos) to promote angiogenesis represents a novel strategy for enhanced wound repair. Saliva is known to accelerate wound healing, but the underlying mechanisms remain unclear. Results Our results have demonstrated that saliva-derived exosomes (saliva-Exos) induce HUVEC proliferation, migration, and angiogenesis in vitro, and promote cutaneous wound healing in vivo. Further experiments documented that Ubiquitin-conjugating enzyme E2O (UBE2O) is one of the main components of saliva-Exos, and activation of UBE2O has effects similar to those of saliva-Exos, both in vitro and in vivo. Mechanistically, UBE2O decreases the level of SMAD6, thereby activating BMP2, which, in turn, induces angiogenesis. Conclusions The present work suggests that administration of saliva-Exos and UBE2O represents a promising strategy for enhancing wound healing through promotion of angiogenesis.
- 29 January 2020
- Published by Springer Nature in Research Square
Open AccessSaliva Exosomes-Derived UBE2O Promotes Angiogenesis in Cutaneous Wounds by Targeting SMAD6
Background Enhancing angiogenesis is critical for accelerating wound healing. Application of different types of exosomes (Exos) to promote angiogenesis represents a novel strategy for enhanced wound repair. Saliva is known to accelerate wound healing, but the underlying mechanisms remain unclear. Results Our results have demonstrated that saliva-derived exosomes (saliva-Exos) induce HUVEC proliferation, migration, and angiogenesis in vitro, and promote cutaneous wound healing in vivo. Further experiments documented that Ubiquitin-conjugating enzyme E2O (UBE2O) is one of the main components of saliva-Exos, and activation of UBE2O has effects similar to those of saliva-Exos, both in vitro and in vivo. Mechanistically, UBE2O decreases the level of SMAD6, thereby activating BMP2, which, in turn, induces angiogenesis. Conclusions The present work suggests that administration of saliva-Exos and UBE2O represents a promising strategy for enhancing wound healing through promotion of angiogenesis.